CARA THERAPEUTICS INC's ticker is CARA and the CUSIP is 140755109. A total of 124 filers reported holding CARA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,951,142 | -37.0% | 1,756,632 | +6.1% | 0.38% | -48.4% |
| Q2 2023 | $4,685,280 | +82126.7% | 1,655,576 | +42.7% | 0.73% | -18.6% |
| Q1 2023 | $5,698 | -54.3% | 1,160,392 | 0.0% | 0.90% | -69.3% |
| Q4 2022 | $12,463 | -99.9% | 1,160,392 | 0.0% | 2.92% | +15.4% |
| Q3 2022 | $10,861,000 | +2.5% | 1,160,392 | 0.0% | 2.53% | +1.2% |
| Q2 2022 | $10,594,000 | -25.8% | 1,160,392 | -1.3% | 2.50% | +29.2% |
| Q1 2022 | $14,281,000 | -10.1% | 1,175,392 | -9.9% | 1.94% | -8.7% |
| Q4 2021 | $15,894,000 | -21.2% | 1,304,903 | 0.0% | 2.12% | -25.7% |
| Q3 2021 | $20,161,000 | +8.3% | 1,304,903 | +0.0% | 2.86% | +39.8% |
| Q2 2021 | $18,617,000 | -34.8% | 1,304,603 | -0.8% | 2.04% | -32.9% |
| Q1 2021 | $28,540,000 | +43.5% | 1,314,603 | 0.0% | 3.04% | +25.5% |
| Q4 2020 | $19,890,000 | +18.9% | 1,314,603 | +0.0% | 2.42% | -10.3% |
| Q3 2020 | $16,725,000 | -34.1% | 1,314,303 | -11.5% | 2.70% | -36.7% |
| Q2 2020 | $25,382,000 | +47.2% | 1,484,303 | +13.7% | 4.27% | +1.4% |
| Q1 2020 | $17,244,000 | -17.6% | 1,305,409 | +0.4% | 4.22% | +36.9% |
| Q4 2019 | $20,938,000 | -7.8% | 1,299,701 | +4.6% | 3.08% | -4.7% |
| Q3 2019 | $22,707,000 | -4.2% | 1,242,201 | +12.7% | 3.23% | +36.7% |
| Q2 2019 | $23,697,000 | +0.4% | 1,102,201 | -8.4% | 2.36% | -15.7% |
| Q1 2019 | $23,604,000 | +50.7% | 1,203,055 | -0.1% | 2.80% | -25.9% |
| Q4 2018 | $15,661,000 | -45.7% | 1,204,654 | 0.0% | 3.78% | +27.9% |
| Q3 2018 | $28,851,000 | +29.4% | 1,204,654 | +3.5% | 2.96% | +14.6% |
| Q2 2018 | $22,299,000 | +71.1% | 1,164,431 | +10.6% | 2.58% | +32.7% |
| Q1 2018 | $13,035,000 | +3.1% | 1,052,933 | +1.9% | 1.94% | -5.7% |
| Q4 2017 | $12,643,000 | -9.7% | 1,032,933 | +1.0% | 2.06% | -24.4% |
| Q3 2017 | $14,003,000 | -10.7% | 1,022,890 | +0.4% | 2.72% | +3.0% |
| Q2 2017 | $15,673,000 | -4.6% | 1,018,390 | +14.0% | 2.64% | +17.4% |
| Q1 2017 | $16,429,000 | +158.1% | 893,390 | +30.4% | 2.25% | -3.6% |
| Q4 2016 | $6,365,000 | – | 685,167 | – | 2.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 2,799,058 | $42,350,000 | 22.29% |
| Chescapmanager LLC | 1,314,603 | $19,890,000 | 2.42% |
| Prosight Management, LP | 294,041 | $4,449,000 | 2.06% |
| DAFNA Capital Management LLC | 261,442 | $3,956,000 | 1.18% |
| Cypress Capital Management LLC (WY) | 81,269 | $1,230,000 | 1.06% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 626,583 | $9,480,000 | 1.02% |
| Carmignac Gestion | 1,851,443 | $28,012,000 | 0.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,465,000 | $37,295,000 | 0.22% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 689,899 | $10,438,000 | 0.20% |
| Ikarian Capital, LLC | 301,700 | $4,565,000 | 0.20% |